Alnylam Files Opposition Against Silence Patent in Europe | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals has opposed a European patent recently issued to Silence Therapeutics, claiming in a document filed with the European Patent Office that the intellectual property is neither new nor inventive, and that the patent does not describe the invention sufficiently clearly.

Notably, the patent in dispute is part of the so-called Zamore IP family. Alnylam's top official earlier this year publicly dismissed a related US patent from the Zamore family as "not worth anything."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.